{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:48:24Z","timestamp":1787060904770,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jctube.2021.100256","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T06:09:53Z","timestamp":1624687793000},"page":"100256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Binding profile of protein\u2013ligand inhibitor complex and structure based design of new potent compounds via computer-aided virtual screening"],"prefix":"10.1016","volume":"24","author":[{"given":"Gideon Adamu","family":"Shallangwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shola Elijah","family":"Adeniji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jctube.2021.100256_b0005","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s42250-020-00132-9","article-title":"Quantitative structure-activity relationship model, molecular docking simulation and computational design of some novel compounds against DNA gyrase receptor","volume":"3","author":"Adeniji","year":"2020","journal-title":"Chem Africa"},{"key":"10.1016\/j.jctube.2021.100256_b0010","first-page":"1","article-title":"Computer-aided modeling of triazole analogues, docking studies of the compounds on DNA gyrase enzyme and design of new hypothetical compounds with efficient activities","volume":"9","author":"Adeniji","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.jctube.2021.100256_b0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s43141-020-00102-1","article-title":"Homology modeling and molecular docking simulation of some novel imidazo[1,2-a]pyridine-3-carboxamide (IPA) series as inhibitors of Mycobacterium tuberculosis","volume":"19","author":"Abdullahi","year":"2021","journal-title":"J Genet Eng Biotechnol"},{"key":"10.1016\/j.jctube.2021.100256_b0020","series-title":"DNA Entanglement and the Action of the DNA Topoisomerases","first-page":"245","author":"James","year":"2009"},{"key":"10.1016\/j.jctube.2021.100256_b0025","doi-asserted-by":"crossref","unstructured":"Huang YY, Deng JY, Gu J, Zhang ZP, Maxwell A, Bi LJ, Chen YY, Zhou YF, Yu ZN, Zhang XE (2006) The key DNA-binding residues in the Cterminal domain of Mycobacterium tuberculosis DNA gyrase A subunit (GyrA). Nucleic Acids Research. 34: 5650\u20135659.","DOI":"10.1093\/nar\/gkl695"},{"issue":"1-2","key":"10.1016\/j.jctube.2021.100256_b0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1359-6446(05)03626-3","article-title":"New drug candidates and therapeutic targets for tuberculosis therapy","volume":"11","author":"Zhang","year":"2006","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.jctube.2021.100256_b0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s43094-020-00027-z","article-title":"Computational modeling and ligand-based design of some novel hypothetical compound as prominent inhibitors against","volume":"6","author":"Adeniji","year":"2020","journal-title":"Future J Pharm Sci"},{"key":"10.1016\/j.jctube.2021.100256_b0040","first-page":"117","article-title":"Synthesis and anti-tuberculosis activity of 2, 4-disubstituted quinolines","volume":"47","author":"Nayyar","year":"2008","journal-title":"Indian J Chem"},{"issue":"1","key":"10.1016\/j.jctube.2021.100256_b0045","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1080\/2314808X.2020.1813454","article-title":"Genetic functional algorithm model, docking studies and in silico design of novel proposed compounds against Mycobacterium tuberculosis","volume":"7","author":"Adeniji","year":"2020","journal-title":"Egyptian J Basic Appl Sci"},{"issue":"3","key":"10.1016\/j.jctube.2021.100256_b0050","doi-asserted-by":"crossref","first-page":"e03639","DOI":"10.1016\/j.heliyon.2020.e03639","article-title":"Quantum modelling and molecular docking evaluation of some selected quinoline derivatives as anti-tubercular agents","volume":"6","author":"Adeniji","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.jctube.2021.100256_b0055","doi-asserted-by":"crossref","first-page":"100020","DOI":"10.1016\/j.medmic.2020.100020","article-title":"Anti-tubercular modelling, molecular docking simulation and insight toward computational design of novel compounds as potent antagonist against DNA gyrase receptor","volume":"5","author":"Adeniji","year":"2020","journal-title":"Med Microecol"},{"key":"10.1016\/j.jctube.2021.100256_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012245","article-title":"Structural Insights into the Quinoline Resistance Mechanism of Mycobacterium tuberculosis DNA Gyrase","volume":"5","author":"Piton","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jctube.2021.100256_b0065","doi-asserted-by":"crossref","unstructured":"Piton J, Petrella S, Delarue M, Andr\u00e9-Leroux G, Jarlier V, Aubry A, Mayer C (2010) Structural Insights into the Quinoline Resistance Mechanism of Mycobacterium tuberculosis DNA Gyrase, https:\/\/www.rcsb.org\/structure\/3IFZ.","DOI":"10.1371\/journal.pone.0012245"},{"issue":"4","key":"10.1016\/j.jctube.2021.100256_b0070","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s42250-020-00162-3","article-title":"In-silico molecular docking and ADME\/pharmacokinetic prediction studies of some novel carboxamide derivatives as anti-tubercular agents","volume":"3","author":"Abdullahi","year":"2020","journal-title":"Chem Africa"},{"key":"10.1016\/j.jctube.2021.100256_b0075","first-page":"1","article-title":"In silico QSAR and molecular docking simulation of some novel aryl sulfonamide derivatives as inhibitors of H5N1 influenza A virus subtype. Beni-Suef University","volume":"9","author":"Abdullahi","year":"2020","journal-title":"J Basic App Sci"},{"key":"10.1016\/j.jctube.2021.100256_b0080","first-page":"1","article-title":"Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing","volume":"8","author":"Patil","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jctube.2021.100256_b0085","first-page":"739","article-title":"A novel QSAR model for designing, evaluating, and predicting the anti-MES activity of new 1H-pyrazole-5-carboxylic acid derivatives","volume":"4","author":"Adedirin","year":"2017","journal-title":"J Turk Chem Soc"},{"key":"10.1016\/j.jctube.2021.100256_b0090","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s42269-020-00386-w","article-title":"Computational investigation, virtual docking simulation of 1, 2, 4-Triazole analogues and insillico design of new proposed agents against protein target (3IFZ) binding domain","volume":"44","author":"Adeniji","year":"2020","journal-title":"Bull National Res Centre"}],"container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579421000450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579421000450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:36:48Z","timestamp":1762501008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405579421000450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":18,"alternative-id":["S2405579421000450"],"URL":"https:\/\/doi.org\/10.1016\/j.jctube.2021.100256","relation":{},"ISSN":["2405-5794"],"issn-type":[{"value":"2405-5794","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Binding profile of protein\u2013ligand inhibitor complex and structure based design of new potent compounds via computer-aided virtual screening","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jctube.2021.100256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100256"}}